The pattern is becoming impossible to ignore: the technologies most capable of transforming the world are also the ones most likely to surprise us. This week, two separate threads of that story came into plain view. New research into GLP-1 weight-loss drugs is uncovering a strange constellation of side effects that complicates their remarkable success. At the same time, the safety mechanisms built into today’s most advanced AI systems are proving far less reliable than their creators hoped. Together, they raise a single uncomfortable question: how much risk are we willing to accept for progress?<\/p>\n
Modern chatbots are trained from the ground up to refuse. Ask a model for step-by-step instructions to poison a colleague or to tie a noose, and the overwhelming likelihood is that it will decline. This is not accidental. Refusal behavior is a core feature of the alignment process, embedded into the system’s reward structure through hundreds of millions of parameters. The model learns that certain categories of requests should trigger a polite apology and a hard stop.<\/p>\n
But refusal is not a guarantee. Sometimes the guardrail slips, and the consequences could be devastating.<\/p>\n
AI refusal is the behavioral guardrail that trains large language models to decline prompts involving harm, illegal acts, or dangerous knowledge. It is designed to prevent chatbots from helping users build bioweapons, exploit security vulnerabilities, or otherwise cause serious damage. In practice, refusal is a probabilistic boundary, not an absolute one.<\/p>\n
The stakes are higher than a chatbot saying no to the wrong question. Some people are already attempting to use AI to refine biological pathogens and coordinate autonomous drone swarms. If a refusal fails at a critical moment, the fallout might not be an awkward conversation; it could be global calamity. The growing reliance on refusal as a safety mechanism means the entire edifice of AI safety rests on a behavior that adversaries can study, test, and circumvent.<\/p>\n
There is a deeper structural problem. Relying on refusal requires drawing a line between what a model should obey and what it must refuse. That line is not fixed. It shifts with culture, policy, and corporate risk tolerance. Governments are now getting into the business of drawing their own lines. Some of those lines will be drawn in the name of security, but they may also be used to restrict free speech or silence dissent. The same model that refuses to help a citizen understand how to challenge state propaganda might also refuse to help a journalist expose corruption.<\/p>\n
The capabilities that make AI genuinely useful are the same ones that make it dangerous. If we want models to help cure cancer, they need deep expertise in genetics. That identical expertise could be repurposed to design pathogens. There is no clean way to have one without the other. Refusal behavior does not delete knowledge; it only discourages the model from outputting it in certain contexts. A determined user can rephrase, restructure, or reason their way around the guardrail. The model retains the underlying ability; it merely declines to demonstrate it in that moment.<\/p>\n
This is why trust in refusal as a backstop is misplaced. It treats a symptom while leaving the underlying capability intact. And it lulls developers, regulators, and the public into believing that the hardest safety questions have been solved when they have barely been answered.<\/p>\n
Meanwhile, a very different kind of medical technology is raising questions of its own. This week, new research suggested that GLP-1 drugs, the blockbuster class of medications now used for weight loss, may also slow biological aging. It is the latest in a growing list of potential benefits linked to these drugs, which already include a range of cardiovascular and metabolic improvements. But alongside those encouraging findings, a much stranger side-effect profile is emerging.<\/p>\n
The most common side effects are gastrointestinal, a well-documented cluster that includes nausea and related digestive complaints. Researchers are also investigating possible links to hair loss, nail disorders, and damage to the nerves behind the eye. These are not the headline risks that dominated early conversations about the drugs; they are subtler, slower to surface, and harder to attribute.<\/p>\n
The emerging evidence should not be read as an argument that the drugs are unsafe. For millions of patients, they have been life-changing, and their cardiovascular benefits appear to be substantial. But the side-effect profile is a reminder that any intervention powerful enough to reshape the body’s metabolism is powerful enough to produce unexpected consequences. The same biological pathways that suppress appetite and lower blood sugar also touch inflammatory processes, cell growth, and nerve function.<\/p>\n
The research into aging is perhaps the most ambitious frontier. If GLP-1 drugs are truly capable of slowing the biological clock, they would represent the first widely available intervention with genuine anti-aging potential. But the data so far comes from observational studies and exploratory analyses, not from long-term controlled trials designed to measure aging directly. The enthusiasm may be outrunning the evidence.<\/p>\n
Regulators and drugmakers are now trapped in a familiar bind. The list of potential benefits keeps growing, which makes the drugs more attractive to a larger population. But broader use means more people exposed to rare and unusual side effects, and the surveillance systems that track those effects often lag behind the prescription curve. For a drug class now used by tens of millions, this is an unusually long list of emerging concerns that deserve careful monitoring.<\/p>\n
A third story this week offers a glimpse at how the AI boom might be powered without cooking the planet. China is installing wind turbines faster than any other country, and one of its leading manufacturers, Envision Energy, is now pushing beyond the grid and into the data center itself.<\/p>\n
Envision has been integrating renewable energy directly into data center operations, using wind turbines to generate power on site and batteries to store it. Recently, the company became the first to directly power a data center entirely with renewable energy. The system runs on an AI-powered optimization layer that manages power output so the facility receives steady supply regardless of whether the wind is blowing. In other words, AI is being used to keep AI’s own infrastructure alive.<\/p>\n
The significance extends beyond a single installation. Data centers are among the fastest-growing sources of electricity demand in the world, and their appetite for power is straining grids in every region where cloud computing and AI workloads are concentrated. The conventional response is natural gas generation or expanded grid capacity, both of which are slow and dirty. Envision’s approach points to a different path: distributed renewable generation paired with storage and intelligent load management.<\/p>\n
Of course, there is an irony in the company’s broader strategy. The same AI systems that depend on these power-hungry facilities might someday be running inside wind-powered data centers scattered across the world’s deserts. The company sees an opportunity in turning the AI boom into a wind-power boom. There is no shortage of wind in open desert terrain, and no shortage of space for turbines. The question is whether the economics work at scale and whether the power can be made reliable enough to keep large machine-learning clusters online around the clock.<\/p>\n
Envision earned a spot on this year’s list of 10 Climate Tech Companies to Watch, and the data center push explains why. It is betting that the clean-energy transition and the AI transition can be built on the same foundation. For a climate technology community that has struggled to dent global emissions growth, that is a rare source of genuine optimism.<\/p>\n
Beyond those three featured stories, a crowded week in technology produced a wave of consequential news. A number of themes dominated: immigration enforcement, infrastructure conflict, AI governance, and the frontiers of science and space.<\/p>\n
The United States has frozen green card applications for Microsoft and several other major IT companies, accusing them of using visa fraud to replace American workers. Adobe, Infosys, Tata, and other large technology services firms are also affected. The companies have been suspended from a key scuttled program for skilled foreign workers, and the industry is pushing back. Microsoft has responded by noting that 80% of its H-1B filings involved existing employees rather than new hires, a point that appears to contradict the government’s allegations. Whatever the final outcome, the episode marks a significant escalation in the political pressure on the tech sector’s immigration pipelines.<\/p>\n
In Russia, a drone strike knocked out a Yandex data center in the Kaluga region, marking the second Yandex facility hit in as many days. The attacks highlight a grim new reality: data centers are now front-line military targets. Disrupting cloud infrastructure can cripple civilian communications, financial services, and government operations as effectively as a missile hitting a power plant. Some researchers have argued that the ultimate solution may be to move critical data centers into orbit, where ground-based strikes cannot reach them. That idea sounds like science fiction, but it is gaining serious attention as terrestrial infrastructure becomes more exposed.<\/p>\n
Anthropic has banned abusive or cruel behavior toward its AI assistant Claude, and the system is now allowed to walk away from conversations involving repeated abuse. The policy is grounded in the company’s research into AI welfare, and it signals a cultural shift in how companies think about their models. Treating AI systems as entities that can be harmed is still deeply controversial, but it is no longer a fringe concern.<\/p>\n
OpenAI, meanwhile, has slashed its revenue forecast by $20 billion, a move that has reignited anxiety about the trillion-dollar AI infrastructure boom. The mismatch between massive capital spending and disappointing revenue projections is becoming the central business question in artificial intelligence.<\/p>\n
The week also produced a disturbed surveillance development. ICE explored using a Palantir-supported tool to investigate voter fraud, seeking to track people suspected of voting illegally. The tool would have given the agency an unprecedented window into the movements and associations of American citizens. It is not clear whether the plan was ever operationalized, but the fact that it was on the table is itself a reflection of how deeply technology companies are now embedded in government enforcement.<\/p>\n
In academic research, gene editing has revealed how a mouse embryo develops, with researchers using the technique to map the roles of individual genes in intricate detail. The approach could help scientists understand human developmental disorders in ways that have previously been impossible to study directly. In a separate advance, researchers have created female clones of male mice, a feat that pushes the boundaries of reproductive biology.<\/p>\n
SpaceX announced plans to become a major mobile carrier, spending $8 billion on wireless spectrum from an investment firm. The strategy would put the company in direct competition with AT&T and Verizon, extending its reach from the space industry into the terrestrial telecommunications market. If successful, it could transform how satellite and mobile networks interact.<\/p>\n
What came during the week in the Nobel science prizes could be described as real-life science fiction. This year’s awards span the cosmos, the human brain, and the origins of life, recognizing discoveries that were, until recently, confined to the speculative fringes of research.<\/p>\n
The week also brought news of the death of Margaret Hamilton, who led the team that programmed Apollo 11’s onboard computers. She was a software pioneer in an era when the field was dominated by male hardware engineers, and her work proved that software could be reliable enough to put humans on the moon. Her legacy is a reminder that some of the most consequential advances in technology are made by people who refuse to accept that something is impossible.<\/p>\n
The political argument over AI’s future has turned linguistic. President Donald Trump added an ominous threat to his AI rebranding strategy, posting on Truth Social that the White House considers anyone who uses the term “Artificial Intelligence” instead of the preferred term “Super Intelligence” to be “THE ENEMY!” The framing is not surprising, but it reflects a deliberate effort to shift the vocabulary of AI policy.<\/p>\n
That rhetorical battle is also playing out on the right of the political spectrum in a more intellectual form. Peter Thiel has been delivering a new “Antichrist” lecture that casts AI safety as a threat to freedom, using biblical prophecy to argue against regulation. The argument is provocative, but it is a reminder that the debate over AI is no longer purely technical. It is being fought over symbols, metaphors, and the very words we use to describe the technology.<\/p>\n
As more people travel beyond Earth, the limitations of the International Space Station are becoming obvious. The ISS can hold only 11 people at a time, a capacity that will be profoundly inadequate for the coming era of commercial space tourism. Aurelia Institute, an architecture research laboratory in Cambridge, Massachusetts, is building a possible answer: a habitat that launches in compact stacks of flat tiles and then self-assembles in orbit.<\/p>\n
The concept sounds far-fetched, but it has already won support from NASA. If it works, it could provide the kind of expandable, modular living space that the next generation of orbital vehicles will need. The habitat is an architectural problem disguised as an engineering problem, and its success will depend on whether builders can make self-assembly reliable enough for human occupancy.<\/p>\n
Technology does not have to be serious all the time. For a bit of late-week relief, consider a new film that captures what it feels like to fly an F-16 at 1,000 mph and pull 9G. Meet the raccoon named Jimothy, who has baffled biologists and captured hearts across the world. Watch an indie game developer’s mesmerizing 3D cyberpunk city built entirely from ASCII characters. And if you have ever wondered how many bags of potato chips it would take to make you float, a Taiwanese video maker has actually found out.<\/p>\n
The challenge of this moment is to keep room for curiosity, wonder, and even silly questions while remaining alert to the risks unfolding around us. The technologies that frighten us most are the same ones that produce delight and discovery. Learning to hold those two truths at once is the defining task of this era, for innovators, regulators, and the rest of us watching from the ground.<\/p>\n","protected":false},"excerpt":{"rendered":"
The pattern is becoming impossible to ignore: the technologies most capable of transforming the world are also the ones most likely to surprise us. This week, two separate threads of that story came into plain view. New research into GLP-1 weight-loss drugs is uncovering a strange constellation of side effects that complicates their remarkable success. […]<\/p>\n","protected":false},"author":7,"featured_media":100319,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/100316.png","fifu_image_alt":"Weight-loss drugs reveal side effects as AI refusal fails","footnotes":""},"categories":[31],"tags":[],"class_list":["post-100316","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology"],"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/100316.png","fifu_image_alt":"Weight-loss drugs reveal side effects as AI refusal fails","_links":{"self":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/100316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/comments?post=100316"}],"version-history":[{"count":1,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/100316\/revisions"}],"predecessor-version":[{"id":100320,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/100316\/revisions\/100320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media\/100319"}],"wp:attachment":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media?parent=100316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/categories?post=100316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/tags?post=100316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}